Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102775886 | 10277588 | 6 | F | 20140327 | 20160901 | 20140704 | 20160906 | EXP | JP-BRISTOL-MYERS SQUIBB COMPANY-20751269 | BRISTOL MYERS SQUIBB | 58.00 | YR | M | Y | 105.00000 | KG | 20160906 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102775886 | 10277588 | 1 | PS | ELIQUIS | APIXABAN | 1 | Oral | 2.5 MG, BID | Y | 202155 | 2.5 | MG | TABLET | BID | |||||
| 102775886 | 10277588 | 2 | SS | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Unknown | 75 MG, QD | Y | 0 | 75 | MG | QD | ||||||
| 102775886 | 10277588 | 3 | SS | BAYASPIRIN | ASPIRIN | 1 | Unknown | 100 MG, QD | U | 0 | 100 | MG | QD | ||||||
| 102775886 | 10277588 | 4 | C | FEBUXOSTAT. | FEBUXOSTAT | 1 | Unknown | TRADE NAME: FEBURIC | U | 0 | 40 | MG | QD | ||||||
| 102775886 | 10277588 | 5 | C | PARIET | RABEPRAZOLE SODIUM | 1 | Unknown | 10 MG, QD | U | 0 | 10 | MG | QD | ||||||
| 102775886 | 10277588 | 6 | C | RENIVACE | ENALAPRIL | 1 | Unknown | 2.5 MG, QD | U | 0 | 2.5 | MG | QD | ||||||
| 102775886 | 10277588 | 7 | C | ARTIST | CARVEDILOL | 1 | Unknown | 2.5 MG, QD | U | 0 | 2.5 | MG | QD | ||||||
| 102775886 | 10277588 | 8 | C | MAGMITT | MAGNESIUM OXIDE | 1 | Unknown | 660 MG, QD | U | 0 | 660 | MG | QD | ||||||
| 102775886 | 10277588 | 9 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | QD | ||||||
| 102775886 | 10277588 | 10 | C | EUGLUCON | GLYBURIDE | 1 | Oral | 2.5 MG, QD | U | 0 | 2.5 | MG | QD | ||||||
| 102775886 | 10277588 | 11 | C | METGLUCO | METFORMIN HYDROCHLORIDE | 1 | Oral | 250MG 2*/DAY | U | 0 | 500 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 102775886 | 10277588 | 1 | Cerebrovascular accident prophylaxis |
| 102775886 | 10277588 | 2 | Product used for unknown indication |
| 102775886 | 10277588 | 3 | Product used for unknown indication |
| 102775886 | 10277588 | 4 | Product used for unknown indication |
| 102775886 | 10277588 | 5 | Product used for unknown indication |
| 102775886 | 10277588 | 6 | Product used for unknown indication |
| 102775886 | 10277588 | 7 | Product used for unknown indication |
| 102775886 | 10277588 | 8 | Product used for unknown indication |
| 102775886 | 10277588 | 9 | Product used for unknown indication |
| 102775886 | 10277588 | 10 | Product used for unknown indication |
| 102775886 | 10277588 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 102775886 | 10277588 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 102775886 | 10277588 | Contraindicated product administered | |
| 102775886 | 10277588 | Haemorrhagic cerebral infarction | |
| 102775886 | 10277588 | Hepatic cancer |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 102775886 | 10277588 | 1 | 20131127 | 0 | ||
| 102775886 | 10277588 | 2 | 20131031 | 0 | ||
| 102775886 | 10277588 | 3 | 20131031 | 0 | ||
| 102775886 | 10277588 | 4 | 20140115 | 0 | ||
| 102775886 | 10277588 | 5 | 20131106 | 0 | ||
| 102775886 | 10277588 | 6 | 20131102 | 0 | ||
| 102775886 | 10277588 | 7 | 20131104 | 0 | ||
| 102775886 | 10277588 | 9 | 20131102 | 0 |